Navigation Links
Pro Quarterback David Garrard Aims to Score Big For Crohn's Disease During the 2009 Football Season

HORSHAM, Pa., Sept. 9 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the In the Zone for Crohn's program with David Garrard, quarterback for the Jacksonville Jaguars((R))(1) will continue this football season to raise awareness and provide funding for Crohn's disease research, education and support. Building on the success of last year's program, which raised $170,000 for the Crohn's & Colitis Foundation of America (CCFA), Centocor Ortho Biotech will again make a donation of $10,000 to the CCFA for each touchdown Garrard scores, passing or rushing, during the 2009 NFL season.

(Photo: )

More information about the In the Zone for Crohn's program can be found at, where visitors can track Garrard's progress throughout the season. Crohn's disease, combined with a related inflammatory bowel disease (IBD) called ulcerative colitis (UC), affects more than 1.4 million Americans.

"I feel fortunate to be able to bring even greater awareness to this often misunderstood condition," said David Garrard, quarterback of the Jacksonville Jaguars. "Through my play on the field and by speaking out on my condition, I hope to continue to further educate the public and be an example to others who are living with Crohn's disease."

The program will kick off with the Jaguars' first game of the season on September 13 and will culminate at the end of the 2009 season. A contribution will be donated to the CCFA based on Garrard's total touchdown performance. The In the Zone for Crohn's program kicked off during the 2008 season. By the end of the season, Garrard helped raise $170,000 for the CCFA through his play on the field.

"David's ongoing commitment to raising awareness of Crohn's disease is commendable and his story is inspirational," said Richard Geswell, President of the Crohn's & Colitis Foundation of America. "Through this continued partnership with Centocor Ortho Biotech Inc. on the In the Zone for Crohn's program, we look forward to enhancing a number of our educational and research programs to ultimately improve the lives of patients struggling with Crohn's disease and ulcerative colitis on a daily basis."

Despite Crohn's disease, Garrard continues to succeed on the field and has scored nearly 50 touchdowns over the past three seasons for the Jaguars. Garrard is entering his third season as their full-time starting quarterback.

(David Garrard is compensated for his participation in the "In the Zone for Crohn's" campaign, which is sponsored by Centocor Ortho Biotech.)

About David Garrard

David Garrard knows first hand the painful, debilitating and often embarrassing effects of Crohn's disease. Prior to the 2004 football season, Garrard began experiencing the excruciating symptoms associated with the disease, lost a significant amount of weight and missed several weeks of pre-season training. Following his diagnosis, David underwent surgery and, in consultation with his doctor, began a treatment regimen. David returned to the playing field by the start of the 2004 season and in 2007 led the team to its first playoff win in eight years.

About Crohn's Disease

Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract, affects approximately 500,000 Americans, including approximately 100,000 pediatric patients. The cause of Crohn's disease is not known, but the disease is associated with an abnormality of the immune system that could be triggered by viral or bacterial infections, a genetic predisposition or diet. Symptoms of Crohn's disease can vary but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss and fever. There is currently no cure for Crohn's disease.

About The Crohn's & Colitis Foundation of America (CCFA)

The Crohn's & Colitis Foundation of America's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 80 cents of every dollar the Foundation spends goes to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance ( and the American Institute of Philanthropy ( For more information, contact the Foundation at 800-932-2423 or visit

About Centocor Ortho Biotech Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Inc. were consolidated in late 2008, and was renamed Centocor Ortho Biotech Inc. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care.

(1) Jacksonville Jaguars is a registered trademark of the National Football League.

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Professional Quarterback Matt Leinart Teams Up With American Red Cross to Promote CPR/AED Awareness
2. Hall-of-Fame Quarterback, John Elway, Chooses Denver's Own Icon LASIK for Laser Vision Correction
3. NFL Quarterback Jay Cutler to Help Families Affected by Diabetes by Joining Lillys Inspired by Diabetes Campaign
4. Audi Teamed Up With Star Quarterback Tom Brady and Celebrities to Support People With Intellectual Disabilities
5. Hall of Fame Quarterback Takes Hit From Prostate Cancer, Urges Men to be Proactive About Their Own Prostate Health
6. WorldHeart Appoints David Pellone Chief Financial Officer
7. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
8. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
9. The Law Offices of John David Hart: Texas Man Sues Medtronic in Body-Snatching Case
10. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
11. St. Davids Medical Center Implements New Robotic Technology to Treat Common Heart Rhythm Disorders
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... The Progressive Dental Institute ... 29 and 30, 2016. The course welcomes dental professionals and members of their ... how to better succeed in the modern dental marketplace. The course combines presentations ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus ... State University. , Their study showed that small molecule analogs that target the ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... Dr. ... With three office locations, patients can visit Dr. Margulies to experience the best available ... to hold the title of "NJ Top Dentist"! , Orthodontics is the branch of ...
(Date:11/30/2015)... ... November 30, 2015 , ... ”Dying Words: The AIDS Reporting ... on December 1, 2015, to coincide with World AIDS Day. The multi-media project will ... covered the AIDS epidemic as he was dying of the disease. , A collaborative ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to RF Safe, the ... scientist at Consumer Reports as supporting a “A Call for Clarity” on cell ... The original Nov 2015 CR story titled, “Does Cell-Phone Radiation Cause Cancer?” ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 iCAD, Inc. (Nasdaq: ... feature its latest solutions for advanced image analysis ... cancer at the Radiological Society of North American ... from November 29 to December 4, ... including iReveal®, an automated breast density assessment solution, ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare and ... Life Sciences Report 2015 . --> Pharmaboardroom releases its ... Latin America , a country of over ... a country of over 122 million people. --> It ... pharmaceuticals, or life sciences insights into the second largest pharma and ...
Breaking Medicine Technology: